In the study by Pieper et al. (25), local antitumor effects of local RT combined with bempegaldesleukin, an investigational CD122-preferential interleukin 2 pathway agonist, resulted in a collaborative antitumor effect in all tumor models tested, and adding an immune checkpoint inhibitor to RT with bempegaldesleukin strengthened the antitumor response and cured most tumor-bearing mice. Here, IL2 is linked to neoplasm.